ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO)

Historical Holders from Q3 2020 to Q3 2025

Symbol
ALXO on Nasdaq
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
53.1M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
27.8M
Holdings value
$51.3M
% of all portfolios
0%
Grand Portfolio weight change
+0%
Number of holders
60
Number of buys
16
Number of sells
-39
Average Value change %
0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Redmile Group, LLC 8.5% $4.78M 4.64M Redmile Group, LLC 30 Jun 2025
HBM Healthcare Investments (Cayman) Ltd. 8.4% +27.1% $2.21M $526K 4.5M +31.3% HBM Healthcare Investments (Cayman) Ltd. 31 Mar 2025
TANG CAPITAL PARTNERS LP 6.3% $1.62M 3.3M TANG CAPITAL MANAGEMENT, LLC 31 Dec 2024
MILLENNIUM MANAGEMENT LLC 6% +18% $5.71M $861K 3.19M +17.8% Millennium Management LLC 17 Oct 2025
FMR LLC 3.4% $881K 1.8M FMR LLC 29 Nov 2024

Institutional Holders of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 27.8M $51.3M +$2.39M $1.83 60
2025 Q2 29.1M $12.6M -$2.79M $0.42 60
2025 Q1 34.8M $21.7M -$4.3M $0.62 83
2024 Q4 41M $68.5M -$8.51M $1.67 85
2024 Q3 45.5M $83.1M -$40.3M $1.82 92
2024 Q2 48.5M $292M -$2.81M $6.03 109
2024 Q1 45.8M $510M -$4.93M $11.15 104
2023 Q4 35.7K $531K +$531K $14.89 2
2023 Q3 33.3M $160M -$6.35M $4.80 76
2023 Q2 34.3M $257M -$6.38M $7.51 74
2023 Q1 35.7M $161M -$6M $4.52 85
2022 Q4 36.4M $411M -$2.05M $11.27 86
2022 Q3 36M $345M +$5.89M $9.57 93
2022 Q2 35.5M $287M -$17M $8.09 90
2022 Q1 36.8M $622M +$3.01M $16.90 93
2021 Q4 36.3M $779M -$56.1M $21.49 101
2021 Q3 34.5M $2.55B +$109M $73.86 111
2021 Q2 33.3M $1.82B -$28M $54.68 101
2021 Q1 32.2M $2.37B +$120M $73.74 90
2020 Q4 30.5M $2.63B +$420M $86.20 85
2020 Q3 27.3M $1.03B +$1.03B $37.74 56